Company
Mirum
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
5
5 still marketed
Novel approvals
3
Approvals since 2021
7
Originals and new uses
Phase 3 trials
12
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Atebrioz approved NovelPriority reviewOrphanSep 25, 2026
- Livmarli approved OrphanApr 10, 2025
- Ctexli approved Priority reviewOrphanFeb 21, 2025
- Livmarli new use OrphanJul 24, 2024
- Livmarli new use OrphanMar 13, 2024
- Livmarli new use Priority reviewOrphanMar 13, 2023
- Livmarli approved NovelBreakthrough therapyPriority reviewOrphanSep 29, 2021
- Cholbam approved NovelPriority reviewOrphanMar 17, 2015
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)Pivotal-lookingRecruiting
Mirum Pharmaceuticals, Inc.Industry
NCT07200908 · 172 participants (planned) · Start Aug 27, 2025 · Primary completion Jun 30, 2027
Drug: Brelovitug 300 mg; Bulevirtide 2 mg and Brelovitug - 300 mg · For: Chronic Hepatitis D Infection
Sites: Graz, Austria; Sankt Pölten, Austria; Brno, Czechia · 57 sites in all
- Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtidePivotal-lookingRecruiting
Mirum Pharmaceuticals, Inc.Industry
NCT07454837 · 120 participants (planned) · Start Feb 26, 2026 · Primary completion Aug 31, 2027
Drug: Brelovitug (BJT-778); Bulevirtide · For: Chronic Hepatitis D
Sites: Graz, Austria; Innsbruck, Austria; Lilienfeld, Austria · 46 sites in all
Marketed drugs (5)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.